M Pharmaceutical Inc. recently announced it has executed on a Letter of Intent to acquire the assets of Cincinnati-based private research and development partnership 40J’s LLC and related companies & technologies. In return for approximately 80 million shares and $1.5 million in cash to be issued or paid over the next 2 years, together with certain milestone payments, the company will acquire 100% of the worldwide rights to these products and technologies. The transaction is subject to due diligence, exchange approval, and other normal closing requirements for transactions of this nature.
Analysis from business intelligence provider GBI Research — Frontier Pharma: Obesity — Identifying and Commercializing First-in-Class Innovation — states that despite the current market's clinical and regulatory challenges, the obesity pipeline is robust and contains a high level of diversity in both molecule types and molecular targets, with 39% of the pipeline products with disclosed molecular targets classified as first-in-class.